X4 Pharmaceuticals, Inc. (XFOR) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $3.58 (-0.97%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 5, 2025 | James Condulis | Stifel Nicolaus | $10.00 | +178.9% |
| Nov 5, 2025 | Stephen Willey | Stifel Nicolaus | $7.50 | +109.2% |
| Aug 29, 2025 | Stephen Willey | Stifel Nicolaus | $9.00 | +151.0% |
| Aug 13, 2025 | Swayampakula Ramakanth | H.C. Wainwright | $3.50 | -2.4% |
| Dec 11, 2022 | Edward Tenthoff | Piper Sandler | $3.00 | -16.3% |
Top Analysts Covering XFOR
XFOR vs Sector & Market
| Metric | XFOR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.26 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +231.9% | +16187.0% | +19.5% |
| P/E Ratio | -5.75 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $6M | $8M | $10M | 2 |
| 2027-12-31 | $7M | $7M | $7M | 2 |
| 2028-12-31 | $107M | $127M | $154M | 2 |
| 2029-12-31 | $277M | $330M | $401M | 1 |
| 2030-12-31 | $599M | $712M | $865M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-1.04 | $-0.87 | $-0.70 | 2 |
| 2027-12-31 | $-1.04 | $-0.83 | $-0.60 | 2 |
| 2028-12-31 | $-1.16 | $-0.70 | $-0.24 | 2 |
| 2029-12-31 | $0.13 | $0.17 | $0.21 | 1 |
| 2030-12-31 | $1.47 | $1.85 | $2.37 | 1 |
Frequently Asked Questions
What is the analyst consensus for XFOR?
The consensus among 1 analysts covering X4 Pharmaceuticals, Inc. (XFOR) is Buy with an average price target of $11.67.
What is the highest price target for XFOR?
The highest price target for XFOR is $10.00, set by James Condulis at Stifel Nicolaus on 2025-12-05.
What is the lowest price target for XFOR?
The lowest price target for XFOR is $3.00, set by Edward Tenthoff at Piper Sandler on 2022-12-11.
How many analysts cover XFOR?
1 analysts have issued ratings for X4 Pharmaceuticals, Inc. in the past 12 months.
Is XFOR a buy or sell right now?
Based on 1 analyst ratings, XFOR has a consensus rating of Buy (2.00/5) with a +231.9% upside to the consensus target of $11.67.
What are the earnings estimates for XFOR?
Analysts estimate XFOR will report EPS of $-0.87 for the period ending 2026-12-31, with revenue estimated at $8M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.